Transcript segment
Baric Transcribed Interview (Redacted), p.105 · baric_ti:utt:00895
Page text: p.105 · original PDF
- Date
- 2026-04-10 09:00 (day precision)
- Type
- transcript segment · interview
- recipient
- Christina Salazar, Harry Kazenoff, David T. Lambeth III, William Henderson, Clark Ervin, Jake Greenberg
- speaker
- Ralph S. Baric
I mean, that's pretty routine. But I
don't believe that, at least from the U.S. side, I don't
believe there was any grant written, that I'm on, where we
proposed to do experiments of furin cleavage sites. Yet,
the reason why I became less interested in it was we
discovered that if you add trypsin exogenously to the
cultures, viruses that you couldn't culture could now be
cultured. And that's because cleavage of S1/S2 boundary,
cleavage of the spike, is essential for the virus to get
into the cell. And if it can't be cleaved, the virus
replicates exceptionally poorly, if at all. But if you add
trypsin, which is a protease, into the media, you could
take viruses that you couldn't culture and now you could
culture them.
So to some extent I was more interested in being able
to have a range of coronaviruses. So, for example,
remdisivir was tested in about 12 or 13 coronaviruses,
including many different sarbecos, from Clade 1 and Clade
2. So we had a really good idea that it would work against
an unknown, and it turned out to be effective against SARS21
coronavirus-2 when used appropriately.